Related Experiment Videos
[Multicenter study of Klimonorm (R) by the Jenapharm firm for treating the climacteric syndrome]
R Czekanowski1, J Stelmachow, S Radowicki
1Szpitala Ginekologiczno-Połozniczego, Warszawie.
Abstract:
In our work we evaluated according to Kupperman Index the effectiveness of treating menopausal signs and symptoms during the therapy with estrogen--progestagen preparation Klimonorm firm Jenapharm. During 6 months observation increase in blood pressure was not observed, neither an increase in body weight in a group of 116 women was not observed. Among these, mean Kupperman index was decreased from 28.38 to 11.6 after 3 months and up to 5.47 after 6 months therapy with Klimonorm. These patients estimated this agent as very good and good in 93.21% tolerated as very good and good in 91.43% and 91.59% of these patients planned to continue treatment with Klimonorm.